Drug Trial Radar · NCT07136454
Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Oak Hill Bio LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Early Access Care LLC
- First posted
- Aug 22, 2025
Design
- Study type
- Expanded access
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
For a patient to be considered for this EAP, they must have consented to participate in the TANGELO Optional Open-label Extension (OOE), and continue to meet the inclusion/ exclusion criteria and have not received any other investigational drug for the treatment of AS between the last dose of the TANGELO OOE and the first dose in the EAP. The Physician making the request for expanded access considers continued treatment via the EAP with rugonersen to be a suitable treatment option for the patient under consideration.
Conditions
- Angelman Syndrome
Interventions
RugonersenDrug
Rugonersen is a selective synthetic 20-mer antisense oligonucleotide (ASO).
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.